… For this reason, we typically choose etanercept when treating patients with psoriasis and
TNFis for patients with LTBI. With the introduction of other biologic therapies such as anti-IL17 …

… on how or when to switch patients who experience failure with TNF inhibitor therapy to another
… In our systematic assessment, we found that switching among all TNF inhibitor treatments …

… synovium of psoriatic patients and the effectiveness of its blockade by these two agents in
psoriasis and … [15] These considerations provide the rationale for using TNF inhibitors in PsA. …

… compare drug survival of ixekizumab to that of TNF inhibitors (TNFi) and non-ixekizumab
IL-17 inhibitors (IL-17i) among real-world patients with PsO in the Corrona Psoriasis Registry. …

… The primary objective of this study was to assess whether patients with psoriasis treated
with TNF inhibitors have a decreased risk of MI compared with those not treated with …

… TNF inhibitors (TNFi) have been proven efficacious in psoriatic arthritis (PsA) in reducing
signs and symptoms of disease and also inhibiting structural joint damage.1–5 In rheumatoid …

… TNF inhibitor-induced psoriasis. Here, we present a literature review on TNF inhibitor-induced
psoriasis and introduce a treatment algorithm for maintaining otherwise effective anti-TNF …

… laboratory characteristics of patients with psoriasis using TNF inhibitors at a dermatology
reference center in Fortaleza. In addition, we aimed to analyze whether anti-TNF treatment has …

… strategy of combining monoclonal TNF-inhibitors with methotrexate in psoriatic arthritis. … in
TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in …

… in patients with psoriasis. In a long-term study of 248 psoriasis patients treated with methotrexate,
10 patients … concluded that methotrexate therapy for psoriasis did not contribute to the …